PubblicazioniPublications    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   HomePagine personaliEvangelistiPubblicazioni
Pubblicazioni - Camilla Evangelisti

 

1. Tabellini G, Billi AM, Fala F, Cappellini A, Evangelisti C, Manzoli L, Cocco L, Martelli AM, Nuclear diacylglycerol kinase- is activated in response to nerve growth factor stimulation of PC12 cells. Cell Signal 2004;16:1263-71. IF= 4.315

2. Tabellini G, Tazzari PL, Bortul R, Evangelisti C, Billi AM, Grafone T, Martinelli G, Baccarani M, Martelli AM, Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. Br J Haematol 2005;130:716-25. IF= 4.711

3. Martelli AM, Fiume R, Faenza I, Tabellini G, Evangelisti C, Bortul R, Follo M, Fala F, Cocco L, Nuclear phosphoinositide specific phospholipase C (PI-PLC)- 1: a central intermediary in nuclear lipid-dependent signal transduction. Histol Histopathol 2005;20:1251-60. IF= 2.096

4. Martelli AM, Follo MY, Evangelisti C, Fala F, Fiume R, Billi AM, Cocco L, Nuclear inositol lipid metabolism: more than just second messenger generation?. J Cell Biochem 2005;96:285-92. IF= 3.263

5. Evangelisti C, Bortul R, Tabellini G, Papa V, Cocco L, Martelli AM, Nuclear expression of diacylglycerol kinases: possible involvement in DNA replication, Eur J Histochem 2006;50:9-13. IF= 2.042

6. Martelli AM, Evangelisti C, Nyakern M, Manzoli FA, Nuclear protein kinase C. Biochim Biophys Acta-Mol Cell Biol Lipids 2006;1761:542-51. IF= 5.162

7. Martelli AM, Nyakern M, Tabellini G, Bortul R, Tazzari PL, Evangelisti C, Cocco L, Phosphoinositide 3-kinase/Akt signalling pathway and its therapeutical implications for human acute myeloid leukemia. Leukemia 2006;20:911-28. IF= 10.431

8. Martelli AM, Faenza I, Billi AM, Manzoli L, Evangelisti C, Fala F, Cocco L, Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. Cell Signal 2006;18:1101-7. IF= 4.315

9. Evangelisti C, Riccio M, Faenza I, Zini N, Hozumi Y, Goto K, Cocco L, Martelli AM, Subnuclear localization and differentiation-dependent increased expression of DGK- in C2C12 mouse myoblasts. J Cell Physiol 2006;209:370-8. IF= 3.839

10. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA, Roles of the RAF/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta-Mol Cell Res 2007;1773:1263-84. IF= 5.019

11. Martelli Am, Evangelisti C, Billi AM, Manzoli L, Papa V, Cocco L, Intranuclear 3'-phosphoinositide metabolism and apoptosis protection in PC12 cells. Acta Bio-Medica De L'ateneo Parmense, 2007,78:113-119.

12. Tazzari PL, Cappellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, Martelli AM, Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/AKT signal tranduction network in human acute myelogenous leukemia blasts. Leukemia 2007;21:427-38. IF= 10.431

13. Evangelisti C, Bortul R, Falà F, Tabellini G, Goto K, Martelli AM, Nuclear diacylglycerol kinases: emerging downstream regulators in cell signaling networks. Histol Histopathol 2007;22:573-9. IF= 2.096

14. Martelli AM, Evangelisti C, Chiarini F, Blacock WL, Papa V, Falà F. The Phosphatidylinositol 3-kinase/Akt/Mammalian target of rapamycin signaling network as a new target for acute myelogenous leukaemia therapy. Cancer Therapy 2007.

15. Tazzari PL, Tabellini G, Bortul R, Papa V, Evangelisti C, Grafone T, Martinelli G, McCubrey JA, Martelli AM, The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007;21:886-96. IF= 10.431

16. Evangelisti C, Tazzari PL, Riccio M, Fiume R, Hozumi Y, Fala F, Goto K, Manzoli L, Cocco L, Martelli AM, Nuclear diacylglycerol kinase- is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. FASEB J 2007;21:3297-307. IF= 5.043

17. Martelli AM, Tabellini G, Bortul R, Nyakern M, Tazzari PL, Evangelisti C, Cocco L, The Phosphoinositide 3-Kinase (PI3K)/AKT signaling pathway as a therapeutic target for the treatment of human acute myeloid leukemia (AML). Curr Signal Transd T 2007;2:246-56.

18. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blacock WL, Billi AM, Manzoli L, McCubrey JA, Cocco L, Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Beside. Curr Med Chem 2007;14:2009-23. IF= 3.853

19. Papa V, Tazzari PL, Chiarini F, Ricci F, Billi AM, Evangelisti C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA, Martelli AM, Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukaemia cells. Leukemia 2008;22:147-60. IF= 10.431

20. McCubrey JA, Abrams SL, Misaghian N, Wong EWT, Steelman LS, Basecke J, Troppmair J, Libra M, Nicoletti F, Molton S, McMahon M, Evangelisti C, Martelli AM, Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. Leukemia 2008;22:2080-90. IF= 10.431

21. Tazzari PL, Tabellini G, Ricci F, Papa V, Chiarini F, Evangelisti C, Martinelli G, Contadini A, Cocco L, McCubrey JA, Martelli AM, Synergic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res 2008;68:9394-403. IF= 9.329

22. Evangelisti C, Astolfi A, Gaboardi GC, Tazzari PL, Pession A, Goto K, Martelli AM, TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-ζ-dependent cell cycle arrest. Cell Signal 2009;21:801-9. IF= 4.315

23. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L, McCubrey JA, Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Inv Drug 2009;18:1333-49. IF= 5.528

24. D’Emilio A, Biagiotti L, Burattini S, Battistelli M, Canonico B, Evangelisti C, Ferri P, Papa S, Martelli AM, Falcieri E, Morphological and biochemical patterns in skeletal muscle apoptosis. Histol Histopathol 2010;25:21-32. IF= 2.096

25. Evangelisti C, Gaboardi GC, Billi AM, Ognibene A, Goto K, Tazzari PL, McCubrey J, Martelli AM, Identification of a functional nuclear export sequence in diacyl glycerol kinase-ζ. Cell Cycle 2010;9:177-182. IF= 4.565

26. Martelli AM, Chiarini F, Evangelisti C, Grimaldi C, Ognibene A, Manzoli L, Billi AM, McCubrey JA, The Phosphatidylinositol 3-kinase/Akt/Mammalian target of rapamycin signaling network and the control of normal myelopoiesis. Histol Histopathol 2010;25:669-680. IF= 2.096

27. Martelli AM, Evangelisti C, Chiarini F, McCubrey JA, The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget 2010; 1:89-103. IF= 6.359

28. Martelli AM, Papa V, Tazzari PL, Ricci F, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Martinelli G, Ottaviani E, Pagliaro P, Horn S, Bäsecke J, Lindner LH, Eibl H, McCubrey JA, Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. Leukemia 2010;24:687-98. IF= 10.431

29. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Cappellini A, Ognibene A, McCubrey JA, The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. Biochim Biophys Acta-Mol Cell Res 2010;1803:991-1002. IF= 5.019

30. Evangelisti C, Ricci F, Tazzari PL, Chiarini F, Battistelli M, Falcieri E, Ognibene A, Pagliaro P, Cocco L, McCubrey JA, Martelli AM, Preclinical testing of the akt inhibitor triciribine in t-cell acute lymphoblastic leukemia. J Cell Physiol 2011;226:822-31. IF= 3.839

31. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, McCubrey JA, The Emerging Role of the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. CANCERS, 2010;2;1576-1596. ISSN: 2072-6694.

32. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, Battistelli M, Falcieri E, Melchionda F, Pession A, Pagliaro P, McCubrey JA, Martelli AM, Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor

NVP-BEZ235, against T-cell acute lymphoblastic leukemia. Cancer Res 2010;70:8097-107. IF= 9.329

33. Martelli AM, Evangelisti C, Follo MY, Ramazzotti G, Fini M, Giardino R, Manzoli L, McCubrey JA, Cocco L, Targeting the phosphatidylinositol 3-Kinase/Akt/mammalian Target of Rapamycin signaling network in cancer stem cells. Curr Med Chem 2011;18;2715-26 IF= 3.715

34. Evangelisti C, Ricci F, Tazzari PL, Tabellini G, Battistelli M, Falcieri E, Chiarini F, Bortul R, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Martelli AM, Targeted Inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-Cell acute lymphoblastic leukemia. Leukemia 2011;25;781-791. IF= 10.431

35. Martelli AM, Evangelisti C, Chappell WH, Abrams SL, Basecke J, Libra M, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA. Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011;25;781-791. IF= 10.431

36. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011;3;192-222 IF= 6.432

37. Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget 2011;2;135-64. IF= 6.359

38. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011;25;1080-94 IF= 10.431

39. McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell W, Bäsecke J, Nicoletti F, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Bonati A, Evangelisti C, Cocco L, Martelli AM. Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. Curr Pharm Design 2012;18;1784-95 IF= 3.452

40. Martelli, AM, Ognibene, A, Buontempo, F, Fini, M, Bressanin, D, Goto, K, McCubrey, JA, Cocco, L, Evangelisti, C. Nuclear phosphoinositides and their roles in cell biology and disease. Crit Rev Biochem Mol 2011;46;436-57 IF= 7.714

41. Okada M, Hozumi Y, Tanaka T, Suzuki Y, Yanagida M, Araki Y, Evangelisti C, Yagisawa H, Topham MK, Martelli AM, Goto K, DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. Cell Signal 2012;24:1573-82. IF= 4.315

42. Martelli AM, Chiarini F, Evangelisti C, Cappellini A, Buontempo F, Bressanin D, Fini M, McCubrey JA, Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget 2012;3:371-94. IF= 6.359

43. Martelli AM, Chiarini F, Evangelisti C, Ognibene A, , Bressanin D, Billi AM, Manzoli L, Cappellini A, McCubrey JA, Targeting the liver kinase B1/Amp-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. Expert Opin Inv Drug 2012;16:729-42. IF= 5.432

44. Simioni C, Neri LM, Tabellini G, Ricci F, Bressanin D, Chiarini F, Evangelisti C, Cani A, Tazzari PL, Melchionda F, Pagliaro P, Pession A, McCubrey JA, Capitani S, Martelli AM, Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. Leukemia 2012;26:2336-2342. IF= 10.431

45. Martelli AM, Tabellini G, Bressanin D, Ognibene A, Goto K, Cocco L, Evangelisti C, The emerging multiple roles of nuclear Akt. Biochim Biophys Acta-Mol Cell Res 2012;1823:2168-2178. IF= 5.019

46. Bressanin D, Evangelisti C, Ricci F, Tabellini G, Chiarini F, Tazzari PL, Melchionda F, Buontempo F, Pagliaro P, Pession A, McCubrey JA, Martelli AM, Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. Oncotarget 2012;3:811-23. IF= 6.359

47. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades. Oncotarget 2012;3:954-87. IF= 6.359

48. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoleti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR

cascade inhibitors: How mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012;3:1608-111. IF= 6.359

49. McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN, Advances in targeting signal transduction pathways. Oncotarget 2012;3:1505-21. IF= 6.359

50. Evangelisti C, Evangelisti C, Bressanin D, Buontempo F, Chiarini F, Lonetti A, Soncin M, Sparta A, McCubrey JA, Martelli AM, Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. Expert Opin Ther Targets 2013;17:921-36. IF= 5.139

51. Buontempo F, Orsini E, Martins LR, Antunes I, Lonetti A, Chiarini F, Tabellini G, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Cappellini A, Barata JT, Martelli AM, Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia. 2014;28:543-53 IF= 10.431

52. Martelli AM, Buontempo F, Evangelisti C GSK-3β: a key regulator of breast cancer drug resistance.. Cell Cycle. 2014;13:697-8.

53. Spartà AM, Bressanin D, Chiarini F, Lonetti A, Cappellini A, Evangelisti C, Evangelisti C, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Martelli AM, Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. Cell Cycle. 2014;13. IF= 4.565

54. Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Bressanin D, Cappellini A, Orsini E, McCubrey JA, Martelli AM, Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia. Int J Oncol. 2014;45:909-18. IF= 3.025

55. Evangelisti C, Evangelisti C, Teti G, Chiarini F, Falconi M, Melchionda F, Pession A, Bertaina A, Locatelli F, McCubrey JA, Beak DJ, Bittman R, Pyne S, Pyne NJ, Martelli AM, Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. Oncotarget 2014;5:7886-901. IF= 6.359

56. Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Neri LM, McCubrey JA, Martelli AM, Autophagy in acute leukemias: A double-edged sword with important therapeutic implications. Biochim Biophys Acta-Mol Cell Res 2015;1853:14-26. IF= 5.019

57. Chiarini F, Evangelisti C, McCubrey JA, Martelli AM, Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci, 2015;36:124-135. IF= 11.539

58. Evangelisti C, Bernasconi P, Cavalcante P, Cappelletti C, D'Apice MR, Sbraccia P, Novelli G, Baldini N, Lemma S, Avnet S, Prencipe S, Squarzoni S, Martelli AM, Lattanzi G, Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. Oncotarget 2015,6:7424-37. IF= 6.359

59. Lonetti A, Cappellini A, Spartà A, Chiarini F, Buontempo F, Evangelisti C, Evangelisti C, Orsini E, McCubrey JA, Martelli AM, PI3K pan-inhibition impairs more efficiently proliferation and survival of t-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. Oncotarget 2015, 6:10399-414 IF= 6.359

60. Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C, Cappellini A, Neri LM, McCubrey JA, Martelli AM, Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. Biochim Biophys Acta-Mol Cell Res 2015, In Press IF= 5.019


Copyright © 2014 Home